[A case of autoimmune hepatitis]

Area of Science:

• Hepatology
• Immunology
• Internal Medicine

Background:

• Autoimmune hepatitis (AIH) is a chronic liver disease of unknown cause.
• It affects all ages, predominantly females, with varied presentations from asymptomatic to acute liver failure.

Observation:

• Diagnosis relies on elevated gammaglobulins, specific autoantibodies (Type 1: ANA/SMA; Type 2: LKM1), and liver histology showing inflammation and necrosis.
• AIH is classified into types based on autoantibody profiles, with mixed forms overlapping with primary biliary cirrhosis and primary sclerosing cholangitis.

Findings:

• Current treatment involves corticosteroids and azathioprine, with budesonide offering a potentially safer alternative for non-cirrhotic patients.
• While effective, treatment is often suspensive, with an 80% relapse rate upon withdrawal.
• Complete biochemical and histological remission improves the likelihood of successful treatment discontinuation after at least two years.

Implications:

• Distinguishing AIH from other hepatitis forms is crucial for appropriate management, potentially aided by diagnostic scoring systems.
• Long-term management strategies aim to minimize side effects while achieving sustained remission.
• Further research may refine treatment protocols to improve outcomes and reduce relapse rates in autoimmune hepatitis.